IPO Porto Research Center

IPO Porto Research Center (CI-IPOP) is a Department of the Portuguese Oncology Institute of Porto/Instituto Português de Oncologia do Porto Francisco Gentil, EPE (IPO Porto), the largest specialized Portuguese cancer center (~10.000 new patients/yr) dedicated to patient care, training, and research in Oncology
Number of publications
Number of ongoing projects
Number of citations
Ongoing Clinical Trials
*Information relative to 2022


IPO Porto is a member of the Organization of European Cancer Institutes (OECI) and is accredited by OECI as a Comprehensive Cancer Center (Porto Comprehensive Cancer Center Raquel Seruca; Porto.CCC) in collaboration with Instituto de Investigação e Inovação em Saúde (i3S), being Coordinator of the National Network of Comprehensive Cancer Centers.

CI-IPOP has the mission to coordinate and implement the research activity of IPO Porto. It is a founding member of the Associated Laboratory Health Research Network (RISE) in which it coordinates the Thematic line 2 (TL2)- “CLINICAL AND TRANSLATIONAL RESEARCH IN ONCOLOGY”. CI-IPOP (R&D Unit of MCTES/FCT HESC-Norte -Porto-776) is an FCT R&D unit since 2004, rated as Excellent in the last international evaluation (2019).

CI-IPOP comprises five translational research groups (Cancer Biology & Epigenetics; Cancer Genetics; Experimental Pathology & Therapeutics; Medical Physics, Radiobiology & Radiation Protection; and Molecular Oncology & Viral Pathology), two clinical groups (Precancerous Lesions and Early Cancer Management and Clinical Oncology) and one group devoted to meet the growing needs on epidemiology of cancer, patient outcome and quality of life, as well as value-based healthcare and sustainability (Epidemiology, Outcomes, Economics and Management in Oncology); along with a Clinical Research Unit, which includes an Early phase clinical trials Unit dedicated to investigator-initiated trials and a recently created Nursing Oncology Research Unit. Additionally, CI-IPOP activity is supported by IPO Porto’s Biobank that is integrated in Biobank.PT Consortium through the National Tumor Bank Network and, since 2021, CI-IPOP is a node of the GenomePT Consortium.


CI-IPOP long-term objective is to understand the pathobiological mechanisms of tumorigenesis and enable Precision Oncology. Patient-centered translational and clinical research is focused on:

  • Development of new diagnostic, prognostic and monitoring biomarkers using liquid biopsies;
  • Identification of novel therapeutic targets to be tested in early phase clinical trials;
  • Improvement of bioimaging, bioinformatics, and outcome assessment tools;
  • Support of the Precision Oncology Program at IPO Porto (POP-IPOP).

CI-IPOP includes almost 300 members of which 75 hold a PhD and 103 a MSc. The IPO Porto staff includes 78 MDs, 49 health technicians, 21 PhD researchers, and 14 PhD students. Moreover, 46 members were supported by fellowships (1 post-doc, 37 PhD students and 8 research assistants) and 29 were MSc students.

Director: Prof. Carmen Jerónimo, PhD

Vice-directors: Prof. Mário Dinis Ribeiro, MD, PhD, and Prof. Rui Medeiros, PhD



The Research Center facilities are distributed across eight different areas in IPO Porto. It includes three translational research laboratories (1, 2 and 3), one dry research laboratory (4), two clinical laboratories (5, 6) and two CI-IPOP Research Units.



In 2022, CI-IPOP members published a total of 256 peer-reviewed scientific articles, and 202 of those were published in journals with impact factor. From all the publications, 139 had at least one category in Q1 from Scimago classification. Among these, 26 were on the “Oncology” category, 12 in “medicine” and 7 were in the “cancer research” category. Of those, the mean impact factor (IF) was 7.2 and the Sum of impact factors was 1464.3. Moreover, 78 articles were published in journals with IF between 5 and 10, with 31 publications with IF above 10.









CI-IPOP was rated as EXCELLENT for the period 2013-2017 and activity plan for 2020-2023 following an international evaluation performed by the panel HEALTH SCIENCES – Clinical and Translational Research organized by FCT. The resulting FCT basic and strategic funding (UIDB-00776-2020 and UIDP-00776-2020) amounts to a total of 1,242,000€ for the period 2020-2023, which includes new PhD researcher contracts. Moreover, the international evaluation awarded eight PhD fellowships to CI-IPOP directly funded by FCT for the same period.



Calendar of Scientific Meetings 2023



225084000 (Ext: 3241)
Edifício A, 2º Piso - Direção do Centro de Investigação